title: A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
abstract: Osteoprotegerin (OPG) is a secreted member of the tumor necrosis factor receptor family, and in previous studies has been shown to regulate osteoclast activity and differentiation. Ablation of the OPG gene in mice results in calcification of the aorta and renal arteries. We have previously reported an association between a single nucleotide polymorphism in the promoter region of OPG and vascular morphology and function in healthy humans. The objective with this study was to confirm our previous results in a larger population, and in addition, to study subjects with hypertension. The OPG genotype was determined by restriction fragment length and the intima-media thickness (IMT) of the common carotid artery was measured by ultrasound in 100 patients with hypertension and left ventricular hypertrophy, and 75 healthy normotensive control subjects. In the hypertensive group subjects with the CC genotype (n=24) showed a significantly increased IMT compared to those with the TC (n=52, p=0.007) and TT (n=24, p=0.009) genotype, in the hypertensive group only (mean +/- SD for TT=0.88 +/- 0.21 mm, TC=0.90 +/- 0.16 mm, CC=1.05 +/- 0.31 mm). The allele distribution did not differ between hypertensive and control individuals. The present study confirms our previous finding and shows that polymorphism in the promoter region of OPG is associated with vascular morphology in hypertensive subjects.
authors.affiliation: Department of Medical Sciences, Uppsala University, Sweden.
authors.forename: H
authors.initials: H
authors.lastname: Brändström
authors.forename: F
authors.initials: F
authors.lastname: Stiger
authors.forename: T
authors.initials: T
authors.lastname: Kahan
authors.forename: H
authors.initials: H
authors.lastname: Melhus
authors.forename: F
authors.initials: F
authors.lastname: Nyström
authors.forename: K P
authors.initials: KP
authors.lastname: öHman
authors.forename: K
authors.initials: K
authors.lastname: Malmqvist
authors.forename: L
authors.initials: L
authors.lastname: Lind
authors.forename: A
authors.initials: A
authors.lastname: Kindmark
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D001262:Atenolol / Q000627:therapeutic use; D002339:Carotid Arteries / Q000473:pathology*; D005260:Female; D005838:Genotype; D006023:Glycoproteins / Q000235:genetics*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D053244:Osteoprotegerin; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics*; D018124:Receptors, Tumor Necrosis Factor; D013548:Sweden
chemical_list: D000319:Adrenergic beta-Antagonists; D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human; D001262:Atenolol